A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon [Rozerem] compared to placebo with zopiclone [Imovane, Zimovane] as a reference arm in adults with chronic insomnia.

Trial Profile

A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon [Rozerem] compared to placebo with zopiclone [Imovane, Zimovane] as a reference arm in adults with chronic insomnia.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Ramelteon (Primary) ; Zopiclone
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Takeda Europe Research & Development Centre
  • Most Recent Events

    • 27 Apr 2010 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Actual initiation date (July 2005) added as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top